Healthcare enters 2026 with a mixed setup. Large-cap pharma and managed care provide cash flow stability, while biotech depends on funding conditions, catalysts, and M&A appetite.
Driven by GLP-1 growth leaders like Eli Lilly, healthcare trades at a 19x Forward P/E. This dashboard tracks valuation trends, equal-weight performance, and sector component data across all 900+ pharmaceutical, biotech, and medical device stocks.
Sector Market Cap
$6.64T
Tracks 1024 stocks · top 50 by market cap
Median YTD Return
+11.7%
Screener universe · median stock return
Median P/E
33.5x
Screener stocks · excludes outliers
Median Dividend Yield
1.89%
Screener stocks · excludes zeros
Sector Screener
Scan the sector leaders, compare valuations and fundamentals, then open the full screener to refine your criteria.
| Ticker | Company | Price | Mkt Cap | P/E | ROE | Div Yield | |
|---|---|---|---|---|---|---|---|
| Eli Lilly and Company | $1353.88 | $1.27T | 43.9 | 101.2% | 0.4% | ||
| Johnson & Johnson | $270.86 | $652.01B | 41.2 | 35% | 1.9% | ||
| AbbVie Inc. | $288.46 | $509.65B | 49.4 | 6214.7% | 2.3% | ||
| Merck & Co., Inc. | $135.09 | $333.65B | 136.7 | 36.9% | 2.4% | ||
| UnitedHealth Group Incorporated | $345.98 | $314.2B | 19.6 | 11.8% | 2.5% | ||
| Novartis AG | $151.91 | $288.74B | 28.8 | 31% | 2.6% | ||
| AstraZeneca PLC | $175.63 | $273.98B | 24.9 | 22.9% | 1.8% | ||
| Thermo Fisher Scientific Inc. | $678.23 | $252.04B | 35.5 | 13.1% | 0.2% | ||
| Amgen Inc. | $439.50 | $237.2B | 25.6 | 106.1% | 2.2% | ||
| Gilead Sciences, Inc. | $168.69 | $209.45B | -54.6 | 40.7% | 1.9% | ||
| Abbott Laboratories | $104.14 | $181.39B | 38.5 | 13% | 2.3% | ||
| Novo Nordisk A/S | $38.51 | $171.01B | 10.3 | 60.7% | 4.4% | ||
| Pfizer Inc. | $27.56 | $157.08B | 39.3 | 8.9% | 6.2% | ||
| Danaher Corporation | $223.21 | $156.91B | 36.4 | 7.1% | 0.6% | ||
| Intuitive Surgical, Inc. | $405.91 | $143.4B | 48.3 | 16.6% | — | ||
| Vertex Pharmaceuticals Incorporated | $523.48 | $132.86B | 33.6 | 22.5% | — | ||
| Medtronic plc | $101.49 | $130.3B | 24.9 | 9.8% | 2.8% | ||
| McKesson Corporation | $1086.45 | $126.79B | 27.0 | — | 0.3% | ||
| Bristol-Myers Squibb Company | $59.38 | $121.27B | 13.2 | 40.4% | 4.2% | ||
| Stryker Corporation | $315.34 | $120.89B | 33.5 | 15.1% | 1.1% | ||
| Sanofi | $46.60 | $111.91B | 24.4 | 10.4% | 4.6% | ||
| CVS Health Corp. | $82.13 | $104.79B | 9.6 | 2.3% | 3.3% | ||
| HCA Healthcare, Inc. | $473.69 | $102.55B | 15.2 | — | 0.6% | ||
| GSK plc | $48.22 | $96.61B | 17.3 | 39.4% | 3.3% | ||
| Regeneron Pharmaceuticals, Inc. | $931.98 | $96.01B | 20.4 | 14.9% | 0.4% | ||
| Elevance Health Inc. | $405.56 | $87.95B | 17.2 | 13.3% | 1.7% | ||
| Moderna, Inc. | $198.69 | $78.84B | -30.6 | -28.9% | — | ||
| Cigna Corporation | $278.97 | $73.8B | 12.3 | 14.3% | 2.2% | ||
| Takeda Pharmaceutical Company Limited | $21.89 | $69.65B | 29.0 | 2.8% | 2.8% | ||
| Cencora, Inc. | $344.56 | $67.04B | 19.0 | 128.4% | 0.7% |
Sector Outlook
Healthcare enters 2026 with a mixed setup. Large-cap pharma and managed care provide cash flow stability, while biotech depends on funding conditions, catalysts, and M&A appetite.
Procedure volumes, GLP-1 demand shifts, and hospital labor normalization are key drivers for providers and devices. Watch drug pricing policy and patent replacement pipelines for large incumbents.
The best opportunities usually come from segment selection, not broad sector timing. Quality compounders and speculative clinical-stage names coexist, so discipline on valuation matters.
Learn
Healthcare under GICS groups companies tied to medicine, patient care, diagnostics, life sciences, or health insurance — from large pharma and biotech to hospital systems, device makers, and health tech vendors.
Drug makers and insurers are valued on cash flow and pricing power. Biotech and devices are more about pipeline quality and product adoption. XLV gives a large-cap snapshot, but the full sector has a wider range of business models.
XLV offers broad exposure to established healthcare leaders. Stock selection is more useful for targeted pharma, managed care, device, or biotech exposure.
Key risks: regulation, reimbursement changes, patent cliffs, trial failures, and utilization shifts. In defensive phases, investors favor insurers and large-cap pharma. In risk-on phases, biotech pipelines and high-growth medtech get attention.
Use the screener to separate recurring cash flow businesses from binary-event stories. Margin stability, balance sheet strength, and valuation work best when compared within the right sub-group.
Explore Further
Healthcare includes pharma, biotech, insurers, hospitals, device makers, diagnostics, and life sciences tools. The screener above shows the sector list with sortable data.
Explore More
Dive into other sector analyses with performance tracking, valuation metrics, and industry breakdowns.
Screen and research technology sector stocks with daily updated valuations, performance charts, and pre-filtered metrics for software, semiconductors, and hardware in 2026.
Screen and research financial services sector stocks with daily updated valuations, yields, and pre-filtered metrics for banks, insurance, and payments in 2026.
Screen and research consumer cyclical sector stocks with daily updated valuations, margins, and pre-filtered metrics for retail, autos, and restaurants in 2026.
Screen and research consumer defensive sector stocks with daily updated valuations, dividend yields, and metrics for food, household goods, and staples retail in 2026.
Screen and research energy sector stocks with daily updated valuations, free cash flows, and metrics for oil, gas, refining, and service companies in 2026.
Screen and research basic materials sector stocks with daily updated valuations, commodity metrics, and pre-filtered metrics for chemicals, metals, and packaging in 2026.
Use our powerful screener to filter Healthcare stocks by market cap, valuation, profitability, and dozens of other fundamental metrics.
Valuation, growth, profitability, technicals
Prices, fundamentals, and estimates refreshed overnight
Bookmark custom screens and track over time
Track the XLV sector ETF performance vs S&P 500. The basket shows equal-weight returns of top 50 stocks by market cap.
Momentum Leaders
Momentum Underperformers
Market Comparison
Against the S&P 500, Healthcare currently trades at 32.9x trailing earnings versus 23.7x for the broad market. This premium is backed by stronger underlying fundamentals, with the sector delivering better margins or returns on equity than the broader index.
Valuation
39% above S&P 500 trailing P/E
| Metric | Healthcare | S&P 500 | Winner |
|---|---|---|---|
| Trailing P/E | 32.9x | 23.7x | S&P 500 cheaper |
| Forward P/E | 22.2x | 20.9x | S&P 500 cheaper |
| EV/EBITDA | 18.5x | 17.3x | S&P 500 cheaper |
78th percentile; range 25.5x to 35.0x
87th percentile; range 18.1x to 35.0x
Quality
Net margin 14.1% vs 27.0%; ROE 120.1% vs 55.8%
| Metric | Healthcare | S&P 500 | Winner |
|---|---|---|---|
| Net Margin | 14.1% | 27.0% | S&P 500 stronger |
| ROE | 120.1% | 55.8% | Sector stronger |
Income
Sector yield 1.41% vs 1.06%
| Metric | Healthcare | S&P 500 | Winner |
|---|---|---|---|
| Dividend Yield | 1.4% | 1.1% | Sector yields more |
These cards are built from the full sector universe, then ranked by market cap so you can see which pockets are leading, rich, resilient, or dangerously concentrated.
Industry Scoreboard
Use this table to spot heavyweights, cheap pockets, leaders, and genuinely beaten-down areas before opening the detailed cards below.
Big Pharma 14 stocks | 45.4% $4.3T | Leading -1.5% median 3M | Fair 15.1x median Fwd P/E | High 23.3% median ROE | Weak 6.3% rev growth | Watchlist Concentrated |
Medical Devices 109 stocks | 9.4% $894.99B | Neutral -24.6% median 3M | Fair 21.1x median Fwd P/E | Mixed -11.3% median ROE | Strong 11.0% rev growth | Watchlist Diversified |
Health Insurers 10 stocks | 7.2% $681.66B | Leading -6.4% median 3M | Cheap 13.5x median Fwd P/E | Mixed 12.0% median ROE | Weak 6.8% rev growth | Mixed One-name heavy |
Life Science Tools 33 stocks | 6.8% $640.85B | Leading +7.6% median 3M | Premium 28.8x median Fwd P/E | Mixed -8.4% median ROE | Weak 4.8% rev growth | Expensive Leader Concentrated |
Vaccines & Infectious Disease 36 stocks | 3.5% $333.68B | Lagging -28.3% median 3M | Cheap 10.3x median Fwd P/E | Mixed -29.7% median ROE | Strong 9.1% rev growth | Beaten Down One-name heavy |
Immunology Biotech 75 stocks | 3.2% $306.42B | Neutral -35.0% median 3M | Cheap 21.7x median Fwd P/E | Mixed -40.0% median ROE | Weak -14.5% rev growth | Mixed Concentrated |
Drug Distributors & Pharmacies 15 stocks | 3.0% $284.7B | Leading -5.0% median 3M | Fair 21.7x median Fwd P/E | Mixed 8.8% median ROE | Weak 4.9% rev growth | Mixed One-name heavy |
Specialty & Generic Drugs 58 stocks | 2.9% $278.05B | Leading -11.1% median 3M | Cheap 9.5x median Fwd P/E | Mixed 5.5% median ROE | Strong 9.5% rev growth | Attractive Diversified |
Rare Disease Biotech 40 stocks | 2.8% $262.79B | Leading -17.9% median 3M | Fair 25.5x median Fwd P/E | Mixed -36.5% median ROE | Average 37.0% rev growth | Mixed One-name heavy |
Healthcare Providers 54 stocks | 2.7% $251.91B | Leading -13.9% median 3M | Cheap 17.8x median Fwd P/E | Mixed 8.7% median ROE | Average 10.2% rev growth | Mixed Concentrated |
Oncology Biotech 144 stocks | 2.4% $228.25B | Lagging -36.8% median 3M | Fair 36.1x median Fwd P/E | Mixed -50.5% median ROE | Average 9.2% rev growth | Mixed Diversified |
Diagnostics & Lab Testing 50 stocks | 2.4% $226.48B | Neutral -20.2% median 3M | Fair 36.8x median Fwd P/E | Mixed -14.1% median ROE | Strong 11.5% rev growth | Watchlist Diversified |
Medical Supplies & Consumables 21 stocks | 1.7% $165.57B | Leading -2.3% median 3M | Fair 20.5x median Fwd P/E | Mixed 6.0% median ROE | Weak 5.3% rev growth | Mixed Concentrated |
Neuroscience Biotech 72 stocks | 1.0% $96.18B | Lagging -35.6% median 3M | Fair 21.4x median Fwd P/E | Mixed -53.8% median ROE | Average 16.2% rev growth | Mixed Concentrated |
Contract Research & Manufacturing 12 stocks | 1.0% $95.27B | Leading +3.0% median 3M | Premium 21.5x median Fwd P/E | Mixed -5.8% median ROE | Weak 1.6% rev growth | Expensive Leader Concentrated |
Healthcare Software & Telehealth 39 stocks | 1.0% $92.51B | Neutral -13.8% median 3M | Fair 21.1x median Fwd P/E | High 2.3% median ROE | Average 6.5% rev growth | Watchlist One-name heavy |
Cell & Gene Therapy 103 stocks | 0.9% $89.61B | Lagging -41.2% median 3M | Premium 24.5x median Fwd P/E | Mixed -57.4% median ROE | Weak -9.2% rev growth | Broken Diversified |
Eye & Dental Care 14 stocks | 0.9% $87.81B | Leading -12.5% median 3M | Fair 18.2x median Fwd P/E | High -1.7% median ROE | Strong 6.0% rev growth | Watchlist Concentrated |
Medical Imaging & Radiation 19 stocks | 0.8% $75.79B | Neutral -35.3% median 3M | Fair 19.6x median Fwd P/E | Weak -37.6% median ROE | Average 14.2% rev growth | Mixed One-name heavy |
Metabolic & Cardiovascular Biotech 44 stocks | 0.4% $41.35B | Lagging -35.3% median 3M | Cheap 128.7x median Fwd P/E | Mixed -46.8% median ROE | Average 30.0% rev growth | Beaten Down Diversified |
Drug Discovery Platforms 27 stocks | 0.3% $23.92B | Neutral -18.8% median 3M | Fair 52.7x median Fwd P/E | Mixed -47.2% median ROE | Strong 33.3% rev growth | Watchlist One-name heavy |
Ophthalmology Biotech 15 stocks | 0.2% $17.91B | Neutral -41.9% median 3M | Premium - median Fwd P/E | Mixed -59.6% median ROE | Weak -9.7% rev growth | Mixed One-name heavy |
Cannabis 14 stocks | 0.0% $2.78B | Lagging -38.6% median 3M | Cheap 13.0x median Fwd P/E | Mixed -8.6% median ROE | Strong 13.1% rev growth | Beaten Down Concentrated |
Other 6 stocks | 0.0% $3M | Neutral -6.1% median 3M | Cheap 0.0x median Fwd P/E | Weak -143.9% median ROE | Strong 139.1% rev growth | Attractive One-name heavy |
Showing 24 of 24 industries in Healthcare.
Setup is a quick read of value, quality, growth, momentum, and concentration together.
Earnings Calendar
Earnings reports are the biggest near-term catalysts for sector moves. Track which names report in the next 60 days and size your positions accordingly.